{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"57.6","value":"46.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"description":"The GCIG CA-125 response was defined as at least 50% reduction in CA-125 levels from baseline. The response must have been confirmed and maintained for at least 28 days.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received single-agent mirvetuximab soravtansine (MIRV) at 6 mg/kg AIBW administered IV on Day 1 of every 3-week cycle (Q3W).","id":"OG000","title":"Mirvetuximab Soravtansine"}],"paramType":"NUMBER","populationDescription":"The CA-125-Evaluable population was defined as all participants who received at least 1 dose of study drug and whose pretreatment sample was ≥2.0 times the upper limit of normal (ULN), within 2 weeks prior to first dose of mirvetuximab soravtansine, and who had at least 1 postbaseline CA-125 evaluation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 15 months","title":"Percentage of Participants With CA-125 Confirmed Clinical Response Per Gynecologic Cancer Intergroup (GCIG) Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}